Emerging Roles of Cell-free Tumor DNA in Oncology The capacity to detect new cancers,
treatment-resistant variants, and tumor heterogeneity by noninvasive technology on the …

Purpose.—Clinical use of analytical tests to assess genomic variants in circulating tumor
DNA (ctDNA) is increasing. This joint review from the American Society of Clinical Oncology …

Earlier detection is key to reducing cancer deaths. Here, we describe a blood test that can
detect eight common cancer types through assessment of the levels of circulating proteins …

DNA methylation represents an annotation system for marking the genetic text, thus
providing instruction as to how and when to read the information and control transcription …

Over the last decades, the concept of precision medicine has dramatically renewed the field
of medical oncology; the introduction of patient-tailored therapies has significantly improved …

Circulating tumour DNA (ctDNA) refers to the fraction of cell-free DNA in a patient's blood
that originates from a tumour. Advances in DNA sequencing technologies and our …

Purpose: Decisions to continue or suspend therapy with immune checkpoint inhibitors are
commonly guided by tumor dynamics seen on serial imaging. However, immunotherapy …

CDK4/6 inhibition substantially improves progression-free survival (PFS) for women with
advanced estrogen receptor-positive breast cancer, although there are no predictive …

Existing methods to improve detection of circulating tumor DNA (ctDNA) have focused on
genomic alterations but have rarely considered the biological properties of plasma cell-free …

Cell-free DNA (cfDNA) refers to short fragments of acellular nucleic acids detectable in
almost all body fluids, including blood, and is involved in various physiological and …